Menarini Group and Insilico Medicine Announce Global Licensing Agreement for Novel KAT6 Inhibitor
KAT6 is a novel target in hormone-sensitive breast tumors and other cancers. KAT6A/B overexpression correlates with poor clinical outcomes in patients with ER+/HER2- breast cancer, the most common subtype.
The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (“Stemline”), a wholly owned subsidiary of the Menarini Group, focused on providing transformational treatments for cancer patients, along with a biotechnology company based on generative artificial intelligence (AI) in … + read more
Menarini Group announces new data on ORSERDU®
Menarini Group announces new data on ORSERDU® (elastrant) at the 2023 San Antonio Breast Cancer Symposium and at ELZONRIS® (tagraxofusp-erzs) at the 65th American Society of Hematology Annual Meeting and Exposition. + read more
Palex Group acquires Burke & Burke
The operation is carried out through Gada Group, a subsidiary with which Palex has been operating in Italy since 2022. + more details
Palex Group acquires Innovamedica, Italian high-tech supplier
The operation is carried out through Gada Group, a subsidiary with which Palex has been operating in Italy since 2022. + more details
The Tradichem Group was created with the aim of technological development in the pharmaceutical markets.
Tradichem SL, Marenostrum Tech, Florida Human Nutrition, Tradichem Industrial Services, Hipering Nutragranules, Tradichem America Corp. and Henares Nutrablend, companies that have been active in Europe and America for many years, now form the Tradichem group. + read more
SEI and UA bring together more than 150 immunologists to introduce new immunotherapies against cancer.
As part of the symposium, the CRIS Cancer Foundation will host a workshop for fifth grade students to promote science education among young children. + read more
Periodontitis is one of the most common pathologies in older people
People over 50 years of age account for 75% of all oral pathology in Spain, with the most common problems being edentulism, periodontal disease and caries. + read more